文献速递针灸推拿中医内科

电针通过抑制JAK2/STAT3通路减轻溃疡性结肠炎铁死亡

Electroacupuncture ameliorates ulcerative colitis by suppressing ferroptosis via the JAK2/STAT3 signaling pathway.
PubMed 文献 · Chin Med · 2026-01-28

本研究以DSS诱导的溃疡性结肠炎(UC)小鼠为模型,探讨电针(EA)对结肠上皮细胞铁死亡及JAK2/STAT3信号通路的调控作用。结果表明,电针可抑制JAK2/STAT3通路、减轻铁死亡和氧化应激、改善肠黏膜屏障并抑制炎症,且效果与JAK2抑制剂AG490相当。

要点

  • 电针可能通过抑制JAK2/STAT3通路减轻UC小鼠结肠上皮细胞铁死亡。
  • 电针改善UC小鼠结肠损伤的效果与JAK2抑制剂AG490干预相当。
  • 铁死亡激活剂erastin可逆转电针的抗铁死亡及结肠保护作用。

核心结论

  • 电针可能通过抑制JAK2/STAT3通路减轻结肠上皮细胞铁死亡,从而缓解DSS诱导的UC小鼠结肠损伤。

研究设计与样本

  • 研究分三阶段:第一阶段以假电针(SEA)组为对照,观察电针(EA)对DSS诱导UC小鼠结肠上皮细胞铁死亡、肠黏膜屏障、氧化应激及炎症的影响。
  • 第二阶段联合使用铁死亡特异性激活剂erastin,验证抑制铁死亡在电针治疗中的关键机制作用。
  • 第三阶段使用JAK2特异性抑制剂AG490干预UC,比较JAK2/STAT3通路抑制与电针治疗UC的效果等效性。

主要发现

  • 与对照组相比,DSS组铁死亡相关指标显著上调,肠黏膜屏障功能受损,氧化应激和炎症反应明显增加,JAK2/STAT3通路表达上调。
  • 与DSS组相比,DSS+EA组结肠组织病理损伤显著改善,结肠上皮细胞铁死亡水平大幅降低,JAK2和STAT3表达相应下调。
  • DSS+EA组治疗效果优于DSS+SEA组。
  • 铁死亡特异性激活剂erastin逆转了电针的抗铁死亡作用及其对结肠的保护作用。
  • 电针改善铁死亡和结肠损伤的效果与JAK2特异性抑制剂AG490干预相当。

临床怎么用

  • 电针可能作为治疗UC的潜在辅助疗法,其机制与抑制JAK2/STAT3通路及铁死亡相关。
  • 临床可考虑将电针用于UC患者,但需结合患者具体情况并在规范治疗基础上进行。

局限性

  • 本研究为动物实验,结论尚未在临床人群中验证。
  • 原文未报告样本量、具体剂量及统计P值等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As an important component of external therapies in traditional Chinese medicine (TCM), the specific mechanism of acupuncture in improving UC has not been fully elucidated. This study investigates the regulatory effects of acupuncture on ferroptosis and the JAK2/STAT3 signaling pathway in colon epithelial cells of dextran sulfate sodium (DSS)-induced UC mice, thereby providing an in-depth exploration of the potential molecular mechanisms underlying acupuncture treatment for UC. METHODS: In the first phase, using a sham electroacupuncture (SEA) group as a control, the effects of electroacupuncture (EA) on ferroptosis, intestinal mucosal barrier function, oxidative stress levels, and the inflammatory response in DSS-induced colon epithelial cells were investigated. Furthermore, the expression levels of the JAK2/STAT3 signaling pathway in colon tissue were examined. In the second phase, the ferroptosis-specific activator erastin was co-administered to further validate the critical mechanistic role of ferroptosis inhibition in EA treatment. In the third phase, the JAK2-specific inhibitor AG490 was used to intervene in UC. A comparative analysis was conducted to assess the effect equivalence between JAK2/STAT3 pathway inhibition and EA treatment for UC, further clarifying the JAK2/STAT3 pathway as a key regulatory target of acupuncture in UC treatment. RESULTS: Compared to the control (Con) group, the DSS group showed significant upregulation of ferroptosis-related indicators, impaired intestinal mucosal barrier function, markedly increased levels of oxidative stress and inflammatory response, along with upregulated expression of the JAK2/STAT3 signaling pathway. Compared to the DSS group, the DSS + EA group exhibited significant improvement in colon histopathological damage, a substantial reduction in ferroptosis levels in colon epithelial cells, and corresponding downregulation of JAK2 and STAT3 expression levels. Notably, the therapeutic effects of the DSS + EA group were superior to those of the DSS + SEA group. The ferroptosis-specific activator erastin reversed the anti-ferroptosis effects of EA and its protective effects on the colon. In addition, the effect of EA treatment in ameliorating ferroptosis and colon injury was comparable to the intervention with the JAK2-specific inhibitor AG490. CONCLUSIONS: EA may alleviate ferroptosis in colonic epithelial cells by inhibiting the JAK2/STAT3 pathway, significantly reducing oxidative stress injury, improving intestinal mucosal barrier integrity, and inhibiting the DSS-induced inflammatory cascade in UC mice. This study provides important modern scientific evidence for the application of acupuncture therapy in treating gastrointestinal diseases.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Zhu T, Wan HY, Qu ZY, et al. Electroacupuncture ameliorates ulcerative colitis by suppressing ferroptosis via the JAK2/STAT3 signaling pathway. Chin Med. 2026. PMID: 41606666. doi:10.1186/s13020-026-01337-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。